SHARMEL KASTEN: Open Payments
NPI 1740365618 · CLOVIS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,769 in 86 payments from 16 companies in 2025. Trend: 2023 $669 · 2024 $1,083 · 2025 $1,769
Food & beverage: $1,769
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 14 | $488 |
| ABBVIE INC. | 27 | $428 |
| Aimmune Therapeutics, Inc. | 21 | $225 |
| Amgen Inc. | 4 | $178 |
| Madrigal Pharmaceuticals | 1 | $121 |
| PFIZER INC. | 3 | $58 |
| Lilly USA, LLC | 3 | $54 |
| Phathom Pharmaceuticals, Inc. | 4 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $27 |
Products named: AIRSUPRA, UBRELVY, VOWST, Repatha, BREZTRI, REZDIFFRA, SYNTHROID, QULIPTA.
Industry payments across CA — which companies pay providers there.
